中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2014年
25期
6-7,8
,共3页
子宫内膜异位症%米非司酮%血管内皮生长因子%肝细胞生长因子
子宮內膜異位癥%米非司酮%血管內皮生長因子%肝細胞生長因子
자궁내막이위증%미비사동%혈관내피생장인자%간세포생장인자
Endometriosis%Mifepristone%Vascular endothelial growth factor%Hepatocyte growth factor
目的：探讨小剂量米非司酮对子宫内膜异位症患者血清血管内皮生长因子(VEGF)和肝细胞生长因子(HGF)的影响。方法126例子宫内膜异位症患者随机分为两组,观察组63例,采用米非司酮6.25 mg,1次/晚；对照组63例,采用米非司酮12.5 mg,1次/晚,两组共治疗3个月。测定治疗前后血清VEGF和HGF。结果治疗后对照组总有效率为90.5%,观察组总有效率为88.9%；两组总有效率比较,差异无统计学意义(χ2=1.62, P>0.05)。两组治疗后患者痛经VAS评分较治疗前均有明显降低(t=6.9216,6.0614, P<0.01),两组治疗后比较,差异无统计学意义(t=0.6218, P>0.05)。治疗后两组患者的血清VEGF和HGF较治疗前均有明显降低(t=5.9248,4.9928, P<0.01；t=3.0616,3.1734, P<0.05)；两组治疗后血清VEGF和HGF比较,差异无统计学意义(t=0.3418,0.2926, P>0.05)。对照组治疗期间有13例发生不良反应,发生率为20.6%；观察组有8例发生不良反应,发生率为12.7%；观察组不良反应发生率明显少于对照组(χ2=5.72, P<0.05)。结论小剂量米非司酮可以明显降低子宫内膜异位症患者血清VEGF和HGF的表达,并且不良反应少。
目的：探討小劑量米非司酮對子宮內膜異位癥患者血清血管內皮生長因子(VEGF)和肝細胞生長因子(HGF)的影響。方法126例子宮內膜異位癥患者隨機分為兩組,觀察組63例,採用米非司酮6.25 mg,1次/晚；對照組63例,採用米非司酮12.5 mg,1次/晚,兩組共治療3箇月。測定治療前後血清VEGF和HGF。結果治療後對照組總有效率為90.5%,觀察組總有效率為88.9%；兩組總有效率比較,差異無統計學意義(χ2=1.62, P>0.05)。兩組治療後患者痛經VAS評分較治療前均有明顯降低(t=6.9216,6.0614, P<0.01),兩組治療後比較,差異無統計學意義(t=0.6218, P>0.05)。治療後兩組患者的血清VEGF和HGF較治療前均有明顯降低(t=5.9248,4.9928, P<0.01；t=3.0616,3.1734, P<0.05)；兩組治療後血清VEGF和HGF比較,差異無統計學意義(t=0.3418,0.2926, P>0.05)。對照組治療期間有13例髮生不良反應,髮生率為20.6%；觀察組有8例髮生不良反應,髮生率為12.7%；觀察組不良反應髮生率明顯少于對照組(χ2=5.72, P<0.05)。結論小劑量米非司酮可以明顯降低子宮內膜異位癥患者血清VEGF和HGF的錶達,併且不良反應少。
목적：탐토소제량미비사동대자궁내막이위증환자혈청혈관내피생장인자(VEGF)화간세포생장인자(HGF)적영향。방법126례자궁내막이위증환자수궤분위량조,관찰조63례,채용미비사동6.25 mg,1차/만；대조조63례,채용미비사동12.5 mg,1차/만,량조공치료3개월。측정치료전후혈청VEGF화HGF。결과치료후대조조총유효솔위90.5%,관찰조총유효솔위88.9%；량조총유효솔비교,차이무통계학의의(χ2=1.62, P>0.05)。량조치료후환자통경VAS평분교치료전균유명현강저(t=6.9216,6.0614, P<0.01),량조치료후비교,차이무통계학의의(t=0.6218, P>0.05)。치료후량조환자적혈청VEGF화HGF교치료전균유명현강저(t=5.9248,4.9928, P<0.01；t=3.0616,3.1734, P<0.05)；량조치료후혈청VEGF화HGF비교,차이무통계학의의(t=0.3418,0.2926, P>0.05)。대조조치료기간유13례발생불량반응,발생솔위20.6%；관찰조유8례발생불량반응,발생솔위12.7%；관찰조불량반응발생솔명현소우대조조(χ2=5.72, P<0.05)。결론소제량미비사동가이명현강저자궁내막이위증환자혈청VEGF화HGF적표체,병차불량반응소。
Objective To investigate the influence of small doses of mifepristone on serum vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with endometriosis. Methods A total of 126 cases of endometriosis were randomly divided into two groups. The observation group (n=63 cases) was treated by mifepristone 6.25 mg for1 time/night, and the control group (n=63 cases) received mifepristone 12.5 mg for1 time/night. The treatment lasted for 3 months. Serum VEGF and HGF were detected before and after treatment. Results The total effective rates were 90.5%in the control group and 88.9%in the observation group. There was no significant difference between the two groups (χ2=1.62, P>0.05). The dysmenorrhea VAS scores of patients after the treatment were lower than before the treatment (t=6.9216, 6.0614, P<0.01), and there was no statistical significance of the difference between the two groups after the treatment (t=0.6218, P>0.05). Serum VEGF and HGF were significantly lowered in two groups after the treatment, comparing with before the treatment (t=5.9248, 4.9928, P<0.01;t=3.0616, 3.1734, P<0.05). The difference of serum VEGF and HGF between the two groups after the treatment had no statistical significance (t=0.3418, 0.2926, P>0.05). In the control group, there were adverse reactions occurred in 13 cases during treatment, and the incidence was 20.6%. There were 8 cases with adverse reactions in the observation group, and the incidence was 12.7%. The incidence of adverse reactions in the control group was obviously lower than that of the observation group (χ2=5.72, P<0.05). Conclusion Small doses of mifepristone can significantly decrease serum VEGF and HGF in patients with endometriosis.
